Therapeutic Area | MeSH |
---|---|
mental disorders | D001523 |
Brand Name | Status | Last Update |
---|---|---|
abilify | New Drug Application | 2025-01-29 |
abilify abilify | New Drug Application | 2013-08-13 |
abilify abilify discmelt | 2008-08-28 | |
abilify asimtufii | New Drug Application | 2025-04-04 |
abilify maintena | New Drug Application | 2025-04-15 |
abilify maintena kit | New Drug Application | 2013-04-02 |
abilify mycite | New Drug Application | 2025-01-31 |
aripiprazole | ANDA | 2025-05-22 |
aripiprazole oral solution | ANDA | 2016-08-31 |
aristada | New Drug Application | 2025-01-28 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
schizophrenia | EFO_0000692 | D012559 | F20 |
schizophrenia spectrum and other psychotic disorders | — | D019967 | — |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Aripiprazole Lauroxil, Aristada, Alkermes Inc | |||
11273158 | 2039-04-06 | U-543 | |
9452131 | 2035-03-19 | U-2402 | |
9526726 | 2035-03-19 | DP | |
10238651 | 2035-03-19 | U-2402 | |
10813928 | 2035-03-19 | U-2402, U-2983 | |
11406632 | 2035-03-19 | U-2402 | |
9193685 | 2033-10-24 | DP | U-543 |
11097006 | 2033-10-24 | DP | U-764 |
9034867 | 2032-11-07 | DP | U-543 |
10226458 | 2032-03-19 | U-543 | |
8431576 | 2030-10-26 | DP | |
8796276 | 2030-06-24 | U-543 | |
10112903 | 2030-06-24 | DP | U-543 |
Aripiprazole Lauroxil, Aristada Initio Kit, Alkermes Inc | |||
10016415 | 2035-09-08 | DP | |
10688091 | 2035-08-17 | DP | |
10849894 | 2035-08-17 | U-543 | |
11154552 | 2035-08-17 | DP |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | — | 1 | 1 | 2 |
Psychotic disorders | D011618 | — | F20.81 | — | — | — | 1 | — | 1 |
Drug common name | Aripiprazole lauroxil |
INN | aripiprazole |
Description | Aripiprazole lauroxil is a dodecanoate ester obtained by formal condensation of the carboxy group of dodecanoic acid with the hydroxy group of 7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-2-oxo-3,4-dihydroquinolin-1(2H)-yl]methanol. A prodrug for aripiprazole, it is used for treatment of schizophrenia. It has a role as a H1-receptor antagonist, a second generation antipsychotic, a serotonergic agonist and a prodrug. It is a dodecanoate ester, a quinolone, a dichlorobenzene, a N-arylpiperazine, a N-alkylpiperazine, an aromatic ether and a delta-lactam. |
Classification | Small molecule |
Drug class | antiulcer agents (benzimidazole derivatives) |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CCCCCCCCCCCC(=O)OCN1C(=O)CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc21 |
PDB | — |
CAS-ID | 1259305-29-7 |
RxCUI | — |
ChEMBL ID | CHEMBL2219425 |
ChEBI ID | — |
PubChem CID | 49831411 |
DrugBank | DB14185 |
UNII ID | 82VFR53I78 (ChemIDplus, GSRS) |